Do Treatment Interventions for Obstructive Sleep Apnoea Reduce Depressive Symptoms in Patients with Comorbid Depression?

INTERVENTION: CPAP therapy. CPAP treatment involves wearing a mask that is attached to a pump that forces air into the airway to hold the airway open during sleep. The dosage will be individually determined during an in‐laboratory CPAP implementation sleep study at the start of the trial. This treatment should be used every night, for 12 months for the CPAP group, or 8 months for the wait‐list group. Usage data is recorded automatically by the device and can be downloaded by the researchers at each visit. The CPAP group will be provided with a 1‐hour CPAP and sleep education session by a sleep scientist or psychologist (either one‐on‐one or in small groups), a CPAP information booklet, and follow up phone call from a sleep scientist after night 1 and night 7 at home to troubleshoot any problems ( 5 minutes duration). The treatment as usual (TAU) group will receive CPAP without additional follow up procedures or education. CONDITION: Depression Obstructive Sleep Apnoea PRIMARY OUTCOME: Daytime Sleepiness (Epworth Sleepiness Scale (ESS) Depression score ‐ (Center for Epidemiology ‐ Depression scale) SECONDARY OUTCOME: Emotional Reactivity Scale and Difficulties in Emotional Regulation Scale INCLUSION CRITERIA: Untreated OSA patients who have been recommended to start CPAP therapy; English fluency; not pregnant or possibility of being pregnant; CES‐D score >16. Patients with a current clinical diagnosis of depression, and who are on antidepressants will also be included.